THe is rekindling the results of a new study into a debate among cardiologists about whether a prescription fish oil product, vasepa, reduces patients’ risk of heart attacks and strokes.
The study does not test vasepa made by Amerson Corp., but another drug called apanova, made by AstraZeneca. But this new trial, called Strength and presented Sunday at a virtual meeting of the American Heart Association, was completely negative, while Vasuspa’s first test, called REDUCE-IT, showed that Wassepa had heart attacks, strokes and Reduces cardiac death by 25%. The vote was not unanimous when the Food and Drug Administration panel voted on whether Wasepa was given broad approval last year. Many cardiologists are struggling to find out what gives.